News

A small but important number of people develop ATTR-CM before age 65 and often have early symptoms that are not limited to the heart.

Real-world evidence shows that new targeted therapies significantly reduce mortality in patients with ATTR-CM.

Researchers interviewed patients with or at risk for ATTR-CM to understand how patient experiences relate to quality of life.

In a phase 2 trial, the investigational antibody treatment coramitug produced a meaningful biomarker improvement in people with ATTR-CM.

Family genetic screening for hereditary ATTR found many carriers and showed that early testing can lead to diagnosis at younger ages.

Intellia Therapeutics paused two phase 3 trials of its CRISPR-based therapy after a patient developed severe liver toxicity.

Structured exercise can improve strength and quality of life in people with ATTR-CM, according to a recent review.

New therapies have greatly expanded the options for treating ATTR-CM, but more research is needed on therapies that remove amyloid deposits.

A phase 3 study recently demonstrated that vutrisiran can lower the risk of gastrointestinal complications among patients with ATTR-CM.

Age should not be the sole reason that potentially helpful disease-modifying therapies are withheld among older patients with ATTR-CM.